MRI-based Radiomics for Predicting Prostate Cancer Grade Groups: A Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies.

Rationale And Objectives: Prostate cancer (PCa) is the second most common cancer among men and a leading cause of cancer-related mortalities. Radiomics has shown promising performances in the classification of PCa grade group (GG) in several studies. Here, we aimed to systematically review and meta-analyze the performance of radiomics in predicting GG in PCa.

Materials And Methods: Adhering to PRISMA-DTA guidelines, we included studies employing magnetic resonance imaging-derived radiomics for predicting GG, with histopathologic evaluations as the reference standard. Databases searched included Web of Sciences, PubMed, Scopus, and Embase. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) and METhodological RadiomICs Score (METRICS) tools were used for quality assessment. Pooled estimates for sensitivity, specificity, likelihood ratios, diagnostic odds ratio, and area under the curve (AUC) were calculated. Cochran's Q and I-squared tests assessed heterogeneity, while meta-regression, subgroup analysis, and sensitivity analysis addressed potential sources. Publication bias was evaluated using Deek's funnel plot, while clinical applicability was assessed with Fagan nomograms and likelihood ratio scattergrams.

Results: Data were extracted from 43 studies involving 9983 patients. Radiomics models demonstrated high accuracy in predicting GG. Patient-based analyses yielded AUCs of 0.93 for GG≥2, 0.91 for GG≥3, and 0.93 for GG≥4. Lesion-based analyses showed AUCs of 0.84 for GG≥2 and 0.89 for GG≥3. Significant heterogeneity was observed, and meta-regression identified sources of heterogeneity. Radiomics model showed moderate power to exclude and confirm the GG.

Conclusion: Radiomics appears to be an accurate noninvasive tool for predicting PCa GG. It improves the performance of standard diagnostic methods, enhancing clinical decision-making.